Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

European Journal of Cancer

Volumn 41, Issue 5, 2005, Pages 799-806

  El Emir, Ethaar ^a   Boxer, Geoffrey M ^a   Petrie, Ingrid A ^a   Boden, Robert W ^a   Dearling, Jason L J ^a   Begent, Richard H J ^a   Pedley, R Barbara ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Colorectal; Combretastatin A 4; Hypoxia; Mice; Perfusion; Tumour parameter; Vasculature; Xenograft

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER MODEL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; HYPOXIA; IMAGING; MEDICAL PARAMETERS; MOUSE; NONHUMAN; NUDE MOUSE; PATHOPHYSIOLOGY; PERFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID TUMOR; TISSUE NECROSIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 14844325322     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.01.001     Document Type: Article

References (35)

1. J. Folkman, and Y. Shing Angiogenesis J Biol Chem 267 1992 10931 10934
2. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
3. J. Denekamp Inadequate vasculature in solid tumours: consequences for cancer research strategies Br J Radiol 24 1992 111 117
4. D.J. Chaplin, and G.J. Dougherty Tumour vasculature as a target for cancer therapy Br J Cancer 80 Suppl. 1 1999 57 64
5. D.W. Siemann, D.J. Chaplin, and M.R. Horsman Vascular-targeting therapies for treatment of malignant disease Cancer 100 2004 2491 2499
6. R.B. Pedley, J.A. Boden, and R. Boden Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow-modifying agents Cancer Res 56 1996 3293 3300
7. R.B. Pedley, S.K. Sharma, and G.M. Boxer Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent Cancer Res 59 1999 3998 4003
8. B.C. Baguley Antivascular therapy of cancer: DMXAA Lancet Oncol 4 2003 141 148
9. G.M. Tozer, C. Kanthou, and C.S. Parkins The biology of the combretastatins as tumour vascular targeting agents Int J Exp Pathol 83 2002 21 38
10. C.M. West, and P. Price Combretastatin A4 phosphate Anticancer Drugs 15 2004 179 187
11. G.R. Pettit, S.B. Singh, and E. Hamel Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 45 1989 209 211
12. G.G. Dark, S.A. Hill, and V.E. Prise Combretastatin A4, an agent that displays potent and selective toxicity toward tumour vasculature Cancer Res 57 1997 1829 1834
13. L. Li, A. Rojiani, and D. Siemann Targeting the tumour vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy Int J Radiat Oncol Biol Phys 42 1998 899 903
14. G.M. Tozer, V.E. Prise, and J. Wilson Combretastatin A-4 phosphate as a tumour vascular-targeting agent: early effects in tumours and normal tissues Cancer Res 59 1999 1626 1634
15. S.M. Galbraith, D.J. Chaplin, and F. Lee Effects of combretastatin A-4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo Anticancer Res 21 2001 93 102
16. M.R. Horsman, and R. Murata Combination of vascular targeting agents with thermal or radiation therapy Int J Radiat Oncol Biol Phys 54 2002 1518 1523
17. D.J. Chaplin, G.R. Pettit, and S.A. Hill Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate Anticancer Res 19 1999 189 196
18. R. Murata, J. Overgaard, and M.R. Horsman Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumour effects of hyperthermia, radiation, and mild thermoradiotherapy Int J Radiat Oncol Biol Phys 51 2001 1018 1024
19. R.B. Pedley, S.A. Hill, and G.M. Boxer Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A4-phosphate Cancer Res 61 2001 4716 4722
20. R.B. Pedley, E. El-Emir, and A.A. Flynn Synergy between vascular targeting agents and antibody-directed therapy Int J Radiat Oncol Biol Phys 54 2002 1524 1531
21. A. Dowlati, K. Robertson, and M. Cooney A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res 62 2002 3408 3416
22. K. Grosios, S.E. Holwell, and A.T. McGown In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug Br J Cancer 81 1999 1318 1327
23. M.R. Horsman, E. Ehrnrooth, and M. Ladekarl The effects of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours Int J Radiat Oncol Biol Phys 42 1998 895 898
24. D.J. Chaplin, and S.A. Hill The development of combretastatin A4 phosphate as a vascular targeting agent Int J Radiat Oncol Biol Phys 54 2002 1491 1496
25. A.S. Bohle, I. Leuschner, and H. Kalthoff Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation Int J Cancer 87 2000 838 843
26. S. Iyer, D.J. Chaplin, and D.S. Rosenthal Induction of apoptosis in proliferating human endothelial cells by the tumour-specific antiangiogenesis agent combretastatin A-4 Cancer Res 58 1998 4510 4514
27. Y. Sheng, J. Hua, and K.G. Pinney Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis Int J Cancer 111 2004 604 610
28. C. Malcontenti-Wilson, V. Muralidharan, and S. Skinner Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model Clin Cancer Res 7 2001 1052 1060
29. D.C. Blakey, F.R. Westwood, and M. Walker Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumour models Clin Cancer Res 8 2002 1974 1983
30. D.A. Beauregard, R.B. Pedley, and S.A. Hill Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS NMR Biomed 15 2002 99 105
31. R.J. Maxwell, J. Wilson, and V.E. Prise Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI NMR Biomed 15 2002 89 98
32. P.F. Rijkin, H.J. Bernsen, and A.J. van der Kogel Application of an image analysis system to the quantification of tumour perfusion and vascularity in human glioma xenografts Microvasc. Res. 50 1995 141 153
33. J. Bussink, J.H. Kaanders, and P.F. Rijken Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide Radiother Oncol 50 1999 173 184
34. P.F. Rijken, H.J. Bernsen, and J.P. Peters Spatial relationship between hypoxia and the (perfused) vascular network in human glioma xenografts: a quantitative multi-parameter analysis Int J Radiat Oncol Biol Phys 48 2000 571 582
35. A.S. Ljungkvist, J. Bussink, and P.F. Rijken Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 54 2002 215 228